Last reviewed · How we verify
NCT02819700: ISDC
Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
trial testing prevalence of behavioural dysexecutive syndrome in Frontotemporal Dementia in 49 participants. Completed in 28 January 2018.
28 January 2018
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 49 |
| Start date | 29 January 2013 |
| Primary completion | 28 January 2018 |
| Estimated completion | 28 January 2018 |
| Sites | 2 locations across France |
Drugs / interventions tested
- prevalence of behavioural dysexecutive syndrome
Conditions studied
- Frontotemporal Dementia — all drugs for Frontotemporal Dementia →
- Huntington Disease — all drugs for Huntington Disease →
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Semantic Dementia — all drugs for Semantic Dementia →
Sponsor
Centre Hospitalier Universitaire, Amiens
Who can join
Adults 40 to 85, any sex, with Frontotemporal Dementia or Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic importance, as they often constitute the initial symptoms of Frontotemporal Dementia (FTD), Semantic Dementia (SD) and Huntington's disease (HD) and they are classically more frequent in vascular dementia (VaD) than in Alzheimer's disease (AD). The presence of these disorders at the stage of Mild Cognitive Impairment (MCI) has only been partially evaluated and would increase the risk of progression to dementia. These classical data are based on non-standardized assessments and non-validated diagnostic criteria. The Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX) has developed a standardized assessment tool for behavioural dysexecutive disorders, the Behavioural Dysexecutive Syndrome Inventory (BDSI) and has validated diagnostic criteria for this syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02819700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Frontotemporal Dementia
Currently open trials in the same condition.
- NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
- NCT06768996 — Music, Social Attention, and Dementia · NA · active not recruiting
- NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting
- NCT06528964 — Proteinopathies Expression in Skin of Neurodegenerative Disorders · recruiting
- NCT06093126 — Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial · Phase 4 · recruiting
Other Centre Hospitalier Universitaire, Amiens trials
Trials by the same sponsor.
- NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
- NCT07071662 — Induction of Labor in Breech Presentation · completed
- NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
- NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
- NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02819700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
- Last refreshed: 20 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02819700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing